TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Total costs of anti-secretory agents
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: first recurrence of symptomatic ECG‐documented supraventricular arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in number of sexual partners
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in unprotected anal intercourse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of motion of the affected knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Double product (myocardial load)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cerebral blood flow velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Postprandial lipid response (chylomicron triacylglycerol)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Risk of low back pain with disability (LBP/D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: angiographic and clinical long-term results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Moderate to severe pain at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endogenous thrombin potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: clot lysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: fibrinolytic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 1-year graft patency rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative DHM at Day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative DHM at Month 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time interval between first and second recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean morning PEFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean systolic/diastolic white-coat effect (WCE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of ambulatory white-coat hypertension (WCH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of self-measured white-coat hypertension (WCH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Levels of CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Glycosylated Hemoglobin A1c (HbA1c) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in episodes of loss of control (LOC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of excess weight gain (BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: INR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in global brain volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Non-motor cognitive symptoms performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median number of postoperative steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in mean nocturnal systolic and diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase in diurnal/nocturnal blood pressure ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of non-dipping
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of RILI
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of children immunized
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immunization coverage rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of CNV at 5 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of GA at 5 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Relative bioavailability of omecamtiv mecarbil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical inactive disease by 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical remission on medication within 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: shoulder mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anhedonia/positive affect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in severity of rosacea symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of cytokines and nitric oxide catabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immediate postoperative facial paralysis
Endpoint domain: Adverse events/effects
Primary endpoint: Final facial outcome
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of surgery for superficial parotidectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Risk of relapse in HBV-treated patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of virological breakthrough
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: coronary artery calcium score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: General effective rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipid metabolism disorder amelioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: opiate use rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative consumption of morphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 90-day complication rates
Endpoint domain: Adverse events/effects
Primary endpoint: comprehension achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in MPA after ADP stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase in CD41 expression after ADP stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: successful treatment completion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cost reduction per case detected and cured
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Need for vasopressor support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Events of hypotension
Endpoint domain: Adverse events/effects
Primary endpoint: subsidence of stems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: corrosion at the neck-stem interface
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: triglycerides reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SF-MPQ score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marinoff dyspareunia scale improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Movement discrimination scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 2 or higher related adverse events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Mortality rate in fulminant hepatic failure (FHF)
Endpoint domain: Mortality/survival
Primary endpoint: supplemental salbutamol treatments required
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients with RCB 0 or I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: cIKS improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline serum IL-6 and IL-2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cosmetic appearance satisfaction rate
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to disappearance of pulmonary rales
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to disappearance of shadows on chest radiograph
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Course of disease duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LV-FS < 28%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: rate of persistent postpartum hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Body resistance measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hydration status estimation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Troponin T concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Abnormalities of hemostasis assay results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: collagen IV and procollagen I production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: self-reports of alcohol craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alcohol-Stroop interference scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: heart rate response to the step test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Children's extreme scores on emotional states
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Current perception thresholds at 250 Hz
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contrast to the anterior epidural space
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Vascular uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incidence of cough at extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical disease severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sleep habits
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Improvement in mean YMRS total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chemosis frequency
Endpoint domain: Adverse events/effects
Primary endpoint: Difficulty to perform procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluid deficit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time taken to perform procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful placement of PICCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Levels of aspartate aminotransferase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Symptoms of gastrointestinal distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of microbiologically confirmed VAP
Endpoint domain: Adverse events/effects
Primary endpoint: Mean time to develop VAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with acquisition of gastric colonization of PPMOs
Endpoint domain: Adverse events/effects
Primary endpoint: lumbar hyperlordosis improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfactory coital activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain during erection
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in potentially inappropriate medications (PIMs) at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical response at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical remission at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: suicidal and self-injurious behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: disease events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of hyperenzymemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Fractional cholesterol absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fecal neutral sterol excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Gastrointestinal symptoms during lipid infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Daily symptom severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 12-month success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total dyspepsia symptoms score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: number of radiopaque barium markers emptied from the stomach
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Seizure index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of dying in the acute ward
Endpoint domain: Mortality/survival
Primary endpoint: Mean daily energy intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in mid-arm circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sE‐selectin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IL‐8 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: cognitive coping
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean fluid accumulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TIMI-3 flow improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Triple clinical end-point (death, reinfarction, recurrent angina)
Endpoint domain: Mortality/survival
Primary endpoint: mean amblyopic eye visual acuity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced visceral hypersensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increased symptom relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced abdominal pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volumetric measurements of lung nodules
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of completed MARS treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bilirubin reduction ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic ionized calcium concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: psychomotor function impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: verbal memory impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiac death incidence rate
Endpoint domain: Mortality/survival
Primary endpoint: Comfort discussing issues
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Knowledge regarding community resources
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Documentation of social questions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patients' preference among instruments
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Disease Activity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aortic PWV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Sensitivity and specificity for differential diagnosis of TBM from PTPM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of eosinophil-derived proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Symptoms of anaphylaxis
Endpoint domain: Adverse events/effects
Primary endpoint: mILOA scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of pin tract infection
Endpoint domain: Adverse events/effects
Primary endpoint: Sputum eosinophilia normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Evaluative response speed to positive vs negative outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight gain of greater than or equal to 5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ejaculatory latency time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of weeks in the follow-up period in which patients were completely recovered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daytime ambulatory BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Signal-to-noise ratio (SNR) gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement of SCID diagnosis with DISH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QALYs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival with favourable neurological outcome
Endpoint domain: Mortality/survival
Primary endpoint: SF-8 scores for general health, physical functioning, and social functioning
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of C-KIT+ cells in the lamina propria and submucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Grade 4 hematologic toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Fever 38.0 degrees C or greater
Endpoint domain: Adverse events/effects
Primary endpoint: Fever 39.0 degrees C or greater
Endpoint domain: Adverse events/effects
Primary endpoint: Hospitalization related to vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Adequate end-of-life discussion
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Positive reactions to soap with MI
Endpoint domain: Adverse events/effects
Primary endpoint: Cortisol concentrations (μg/dl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: cervical range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Uptake in the right olfactory bulb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Biancardi-Stroppa Test accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biancardi-Stroppa Test rapidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of meningeal dissemination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BP responses to mental arithmetic
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ease of use of Brenzys autoinjector compared to Enbrel autoinjector
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recommendation of Brenzys autoinjector over Enbrel autoinjector
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Preference for switching to Brenzys autoinjector
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Weight loss at 18 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in knowledge of REACT-targeted symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time of onset of sensory blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achieving T5 level sensory blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual acuity >+0.5 logMAR unit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anti-diphtheria/anti-tetanus concentrations ≥1.0 IU/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: soft tissue thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes